Sarepta Therapeutics (NASDAQ:SRPT) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Monday, Benzinga reports. They currently have a $182.00 price target on the biotechnology company’s stock.

SRPT has been the topic of a number of other reports. Leerink Partners boosted their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 14th. Citigroup reduced their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Raymond James restated an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $182.95.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $127.31 on Monday. The stock has a market cap of $12.03 billion, a PE ratio of 1,157.36 and a beta of 0.82. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $173.25. The firm has a fifty day moving average price of $129.00 and a 200-day moving average price of $132.39. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the prior year, the business posted ($0.27) EPS. Sarepta Therapeutics’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities analysts anticipate that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Michael Andrew Chambers acquired 37,038 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. raised its position in shares of Sarepta Therapeutics by 896.5% in the 3rd quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 511 shares in the last quarter. VitalStone Financial LLC bought a new position in Sarepta Therapeutics in the third quarter worth about $327,000. UMB Bank n.a. lifted its position in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 197 shares during the last quarter. Connective Portfolio Management LLC bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at about $1,624,000. Finally, Handelsbanken Fonder AB grew its position in shares of Sarepta Therapeutics by 12.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 23,815 shares of the biotechnology company’s stock worth $2,974,000 after buying an additional 2,600 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.